Phase 1 Study of PAS-004, a MEK (1/2) Inhibitor, in MAPK Pathway-driven Advanced Solid Tumors with RAS, NF1, or RAF Mutations or Post-BRAF/MEK Inhibition Failure

The primary objective of this study is to evaluate the **safety** and **tolerability** of PAS-004, a MEK (1/2) inhibitor, in patients with advanced **solid tumors** driven by the MAPK pathway, specifically those with documented RAS, NF1, or RAF mutations, or in patients who have failed BRAF/MEK inhibition. This is clinically relevant as it aims to determine the potential of PAS-004 as a therapeutic option for patients with these specific genetic mutations, who may have limited treatment alternatives.

The clinical trial involves a total of **12 participants** diagnosed with **solid tumors**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, and there are no specific lifestyle considerations such as diet or physical activity mentioned. The selection criteria for the trial population have not been detailed by the sponsor.

The clinical trial is designed as a **Phase 1** open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PAS-004, a MEK (1/2) inhibitor, in patients with MAPK pathway-driven advanced **solid tumors**. The study targets individuals with a documented RAS, NF1, or RAF mutation or those who have failed BRAF/MEK inhibition. The trial is scheduled to commence recruitment on May 15, 2024, and is expected to conclude by September 15, 2026. Participants will be involved in a series of study visits, beginning with an inclusion visit to assess eligibility based on specific criteria. This initial screening will determine the suitability of candidates for participation in the trial.

Following the inclusion visit, participants will undergo regular follow-up visits to monitor their response to the treatment and assess any adverse effects. These visits are crucial for collecting data on the pharmacokinetics and pharmacodynamics of PAS-004. The end-of-study visit will mark the conclusion of a participant's involvement, where final assessments will be conducted to evaluate the overall impact of the treatment. The expected duration of participant involvement will vary depending on individual response and tolerance to the treatment. Conditions that may lead to early termination from the study include significant adverse reactions or the participant's decision to withdraw consent. The trial's open-label design allows for direct observation of the drug's effects, providing valuable insights into its potential therapeutic benefits for patients with advanced solid tumors.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Furthermore, the documentation lacks information on **participant compliance monitoring** and any additional relevant details about drug administration or dosing schedules. The absence of these details limits the ability to provide a comprehensive description of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The estimated recruitment start date is May 15, 2024, with an anticipated end date of September 15, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically focus on safety and dosage, with preliminary efficacy assessments often included. The trial will likely involve regular monitoring and data collection at predetermined intervals to evaluate the intervention's impact on the targeted medical condition. The analysis will be conducted using scientifically validated methods appropriate for early-phase clinical research. The results will contribute to understanding the intervention's potential benefits and inform subsequent trial phases.